secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0001193125-24-149336
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia shareholders elect directors, approve 2024 equity plan at annual meeting
-------------------------------------------------------------------------------

- Julian C. Baker, Stephen R. Biggar, and Daniel B. Soland elected as Class II directors.
- 2024 Equity Incentive Plan approved with 131.3M votes for, 9.4M against.
- Say-on-pay advisory vote passed with 132.99M for, 7.64M against.
- Ernst & Young ratified as independent auditor for FY2024 with 150.0M for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312524149336/0001193125-24-149336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312524149336/d27582d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-149336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer